<DOC>
	<DOCNO>NCT00134160</DOCNO>
	<brief_summary>The purpose study investigate whether high-dose angiotensin II receptor blocker ( ARB ) monotherapy combination therapy ARB calcium channel blocker effective reduce incidence cardiovascular event Japanese elderly high-risk hypertensive patient adequately control standard dose ARB alone .</brief_summary>
	<brief_title>OlmeSartan Calcium Antagonists Randomized ( OSCAR ) Study</brief_title>
	<detailed_description>Hypertension one major risk factor cardiovascular disease . It also important elderly hypertensive patient strictly reduce blood pressure prevent cardiovascular event . Although angiotensin II receptor blocker ( ARBs ) increasingly use antihypertensive treatment recently , study perform Japan assess difference high-dose ARB monotherapy combination therapy ARB calcium channel blocker ( CCB ) prevention cardiovascular disease patient whose blood pressure well control ARB monotherapy . OSCAR-study multicenter , active-controlled , 2-arm parallel group comparison , prospective randomize open blind end-point ( PROBE ) design study . The dose administer olmesartan medoxomil 20mg/day ARB monotherapy 'Step 1 ' period . If blood pressure adequately control treatment well tolerate dose change olmesartan medoxomil 40mg/day high-dose ARB monotherapy group , olmesartan medoxomil 20mg/day CCB combination therapy group 'Step 2 ' period . At least 500 patient enrol group , follow-up duration 3 year . The primary objective compare incidence composite fatal non-fatal cardiovascular event , cause mortality two treatment group .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Outpatients age 65 year old , less 85 year ( time inform consent ) , regardless sex Current antihypertensive treatment monotherapy SBP ≥ 140mmHg DBP ≥ 90mmHg sit position two measurement two clinic visit At least one follow risk factor : Diabetes mellitus Type 2 ; History cerebral infarction , cerebral hemorrhage , subarachnoid hemorrhage , transient ischemic attack ( 6 month give informed consent ) ; Diagnosis asymptomatic cerebrovascular disease ; History myocardial infarction ( 6 month give informed consent ) ; Diagnosis angina pectoris heart failure ( New York Heart Association [ NYHA ] functional classification I II ) ; Diagnosis leave ventricular hypertrophy ( thickness wall interventricular septum ≥ 12mm echocardiography Sv1+Rv5 ≥ 35mm electrocardiography inform consent ) ; Diagnosis aortic aneurysm ; History aortic dissection ( 6 month give informed consent ) ; Diagnosis arteriosclerotic peripheral arterial obstruction ( Fontaine classification 2 4 ) ; Serum creatinine : 1.22.5mg/dL ( male ) ; 1.02.5mg/dL ( female ) ; Proteinuria : ≥ +1 ( ≥ 0.3g/g･Cr . estimate 24hour urine collection random urinary protein correct urine creatinine ) . Secondary hypertension malignant hypertension Heart failure ( NYHA functional classification III IV ) Required treatment malignant tumor Serious liver renal dysfunction ( serum creatinine &gt; 2.5mg/dL dialysis treatment ) Not appropriate change test drug current therapy hypertension coronary disease ( i.e . calcium channel blocker , βblockers , thiazide diuretic , etc . ) History serious adverse drug reaction angiotensin II receptor blocker calcium channel blocker Patients serious reason ( i.e . illness , significant abnormality , etc . ) investigator judge inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Aged</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
	<keyword>Calcium Channel Blockers</keyword>
	<keyword>Combination Drug Therapy</keyword>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>